THOR GmbH	OIT, CAS 26530-20-1 J	uly, 2007
Section A6.3.1 J Annex Point A6.3	Short-term repeated dose toxicity test 28 days oral exposure study	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [X]	Technically not feasible [] Scientifically unjustified [X]	
Limited exposure []	Other justification []	
Detailed justification:	A 90 day oral toxicity study in the rat (Section A6.4.1-02) and a 90 day oral toxicity study in the dog (Section A6.4.1-01) is available.	
	Sufficient data on the oral exposure of OIT is available, further studies are not deemed to be necessary. The risk assessment does not indicate that a further study is necessary.	
Undertaking of intended data submission []	Not applicable	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	01/04/2009	
Evaluation of applicant's justification		
Conclusion	Acceptable	
Remarks	The UK CA considers this justification acceptable according to the data requirements of the BPD ('[short term repeated dose toxicity studies] are required where an adequate sub-chronic toxicity study is available in a re-	
	COMMENTS FROM OTHER MEMBER STATE (specify)	
Date	Give date of comments submitted	
Evaluation of applicant's justification	Discuss if deviating from view of rapporteur member state	
Conclusion	Discuss if deviating from view of rapporteur member state	
Remarks		

Section A6.3.2 J	Short-term repeated dose toxicity test
Annex Point A6.3	28 days dermal exposure study

THOR GmbH	OIT, CAS 26530-20-1	July, 2007
Section A6.3.2 J Annex Point A6.3	Short-term repeated dose toxicity test 28 days dermal exposure study	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [X]	Technically not feasible [] Scientifically unjustified [X]	
Limited exposure []	Other justification []	
Detailed justification:	A 90 day dermal toxicity study in the rat is available (Section A6.4.2-01).	
	Sufficient data on the dermal exposure of OIT is available, further studies are not deemed to be necessary. The risk assessment does not indicate that a further study is necessary.	
Undertaking of intended data submission []	Not applicable	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	01/04/2009	
Evaluation of applicant's justification		
Conclusion	Acceptable	
Remarks	The UK CA considers this justification acceptable according to the data requirements of the BPD ('[short term repeated dose toxicity studies] ar required where an <i>adequate</i> sub-chronic toxicity study is available in a required where an <i>adequate</i> sub-chronic toxicity study is available.	e not
	COMMENTS FROM OTHER MEMBER STATE (specify)	
Date	Give date of comments submitted	
Evaluation of applicant's justification	Discuss if deviating from view of rapporteur member state	
Conclusion	Discuss if deviating from view of rapporteur member state	
Remarks		

Section A6.4.1-01		Subchronic toxicity (oral)	
Annex IIA6.4		90 days dietary toxicity study in dogs	
		1 REFERENCE	Official use only
1.1	Reference	ACTICIDE® OIT (2-n-Octyl-4-isothiazolin-3-one) in male and female dogs, unpublished	
1.2	Data protection	Yes	
1.2.1 1.2.2	Data owner	THOR GmbH, Germany	
1.2.3	Criteria for data protection	Data submitted on existing A.S. for the purpose of its entry into Annex I.	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	Guideline study	Yes	
		OECD Guideline no. 409, 1998	
		EC Directive 87/302/EEC, Part B: No. L 133, 1988	
		OPPTS 870.3050, EPA 712-C-98-200, 1998	
2.2	GLP	Yes	
2.3	Deviations	Yes	
		 No clinical observations were entered in the computer on 27 August 2004. 	
		Evaluation: Sufficient data were available to evaluate the clinical signs properly.	
		2. The following tissues were not available for histopathology:	
		Animal 1: thymus.	
		Animal 18: one parathyroid.	
		Evaluation: Sufficient tissues were available for evaluation.	
		 With the exception of male nos. 41 and 42, all group 7 animals inadvertently received 6000 ppm diet on day 12 of the pretest period. 	
		Evaluation: Pretest blood was already collected at an earlier stage. Animals were returned to pretest diet immediately on day 13. This	
		incidental occurrence was therefore considered to have no adverse	
		effect on the study results obtained in the treatment phase.	
		3 MATERIALS AND METHODS	
3.1	Test material	As given in section 2	
3.1.1	Lot/Batch number	Acticide® OIT,	
3.1.2	Specification	Technical grade	
3.1.2.1	Description	Amber solid to liquid depending on ambient temperature	
3.1.2.2	Purity		
3.1.2.3	-	Stable	
	-		

3.2 Test Animals Non-entry field

Section	on A6.4.1-01	Subchronic toxicity (oral)	
Annex IIA6.4		90 days dietary toxicity study in dogs	
3.2.1	Species	dog	
3.2.2	Strain		
3.2.3	Source		
3.2.4	Sex	Male and female	
3.2.5	Age/weight at study initiation	Groups 1-4: Approximately 8-9 months Groups 5-7: Approximately 7-8 months	
3.2.6	Number of animals per group	4 animals/sex/group	
3.2.7	Control animals	Yes	
3.3	Administration/ Exposure	Oral	
3.3.1	Duration of treatment	At least 90 days	
3.3.2	Frequency of exposure	daily	
3.3.3	Postexposure period	none	
3.3.4	<u>Oral</u>		

Section A6.4.1-01

Subchronic toxicity (oral)

90 days dietary toxicity study in dogs

Annex Point IIA6.4.1

3.3.4.1 Type

3.3.4.2 Dose

iı	in food		
	Group	Dose Level ppm	
	1 ²	0	
	2	100	
	3	300	
	4	1000	
	5 ³	0	
	6	3000	
	7	4500 ¹	

1 Animals received 6000 ppm diet on days 1-8. From day 9-12, treatment of group 7 animals at 6000 ppm was discontinued for ethical reasons, based on a continuous and significantly reduced food intake and reduced body weights observed so far at 6000 ppm.

From day 9 to 12, group 7 animals received Standard dog maintenance pelleted food (Altromin diet 4119 extrudat) supplied by Altromin GmbH (Lage, Germany) mixed with ½ can of Hill's Prescription Diet (Hill's Pet Nutrition BV., the Netherlands)).

On day 13, group 7 animals were fasted for blood collection on day 14.

From day 14-21, group 7 animals received diet with a dose level of 4500 ppm.

From day 22-30, group 7 animals inadvertently received the 6000 ppm instead of 4500 ppm diets.

From day 31 onwards, these animals again received test diet with a dose level of 4500 ppm.

The nominal dose level of 4500 ppm is mentioned throughout the document.

- ² Control group for groups 2-4.
- ³ Control group for groups 6-7.

food consumption per day: 250 grams per animal.

From day 64 onwards, group 1-4 animals were offered the test diet once daily at 0.275 kg/animal/day and group 5-7 animals received 0.300 kg/animal/day from day 79 onwards in the early morning since a higher food supply was considered more appropriate based on their age/body weight development.

- 3.3.4.3VehicleNot applicable.3.3.4.4Concentration in
vehicleNot applicable.3.3.4.5Total volume
appliedNot applicable.3.3.4.6Controlsplain diet
- 3.4 Examinations

Section A6.4.1-01 Annex Point IIA6.4.1		Subchronic toxicity (oral) 90 days dietary toxicity study in dogs
3.4.1	Observations	
3.4.1.1	Clinical signs	yes, at least once daily during pretest and treatment
3.4.1.2	Mortality	Yes, at least twice daily
3.4.2	Body weight	Yes, twice during pretest, weekly during treatment and on the day of necropsy
3.4.3	Food consumption	Yes, daily, except over days when urine was collected.
3.4.4	Water consumption	Not measured.
3.4.5	Ophthalmoscopic examination	Yes at Pre-test: All animals at week 13: All animals
3.4.6	Haematology	 yes During pretest Week 4 Week 13 additionally on group 5 and 7 animals in week 2 for health status monitoring.
3.4.7	Clinical Chemisty	 White blood cells, Red blood cells, Haemoglobin, Haematocrit, Mean corpuscular volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, Platelets, Red blood cell distribution width c.v., Differential leucocyte count (Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils), Reticulocytes, Prothrombin time, Partial thromboplastin time. yes During pretest Week 4 Week 13 additionally on group 5 and 7 animals in week 2 for health status monitoring.
3.4.8	Urinalysis	 Aspartate aminotransferase, Alanine aminotransferase, Alkaline phosphatase, Gamma glutamyl transferase, Lactate dehydrogenase, Glutamate dehydrogenase, Bilirubin, total, Glucose, Creatinine, Urea, Protein, total, albumin, globulin, Albumin Globulin ratio, Cholesterol, total, Triglycerides, Phospholipids, Sodium, Potassium, Chloride, Calcium, Phosphorus. yes During pretest Week 4 Week 13 additionally on group 5 and 7 animals in week 2 for health status monitoring.
		Volume, Colour, Clarity, Specific gravity, pH, Protein, Glucose Ketone, Bilirubin, Blood, Leucocytes, Nitrite, Urobilinogen, Sediment (white blood cells, red blood cells, casts, epithelial cells, crystals, bacteria, other)

Section A6.4.1-01 Annex Point IIA6.4.1		Subchronic toxicity (oral) 90 days dietary toxicity study in dogs	
3.5	Sacrifice and pathology		
3.5.1	Organ Weights	yes Adrenals, Pituitary gland, Brain, Prostate, Epididymides, Spleen Heart, Testes, Kidneys, Thymus, Liver, Thyroid with parathyroids Ovaries, Uterus	
3.5.2	Gross and histopathology	yes	
		- all tissues collected at the control groups, and group 4	scheduled sacrifice from all animals of the and 7
		 all tissues from all animal spontaneously or were sacr all gross lesions 	s of all dose groups which died ificed in extremis
		animal in groups 4 and 7 th	eatment-related changes in the organs of any e histological examination was extended to animals of groups 2, 3 and 6 (males and/or
		Tattoo (not processed)	Pituitary gland
		Adrenal glands	Prostate gland
		Aorta	Rectum
		Brain (medulla, pons,	Salivary gland (parotid, sublingual,
		Caecum	Sciatic nerve
		Cervix	Skeletal muscle
		Colon Duodenum	Skin +Mammary gland area, males and females (pelvic, left and right)
		Eyes, optic nerve and lacrimal Gall bladder	Spinal cord (cervical, thoracic, lumbar) Spleen
		Heart	Sternum
		Ileum	Stomach
		Jejunum	Testes and Epididymides
		Kidneys	Thymus
		Liver	Thyroids
		Lung	Tongue
		Lymph node (mandibular,	Trachea
		Oesophagus	Urinary Bladder
		Ovaries	Ureter
		Pancreas	Uterus
		Parathyroid glands	Vagina
		Peyer's patches (jejunum,	All gross lesions
3.5.3	Other examinations	None	
3.5.4	Statistics	None	
3.6	Further remarks	Dose levels for groups 1-4	(0, 100, 300 and 1000 ppm) were based on nge finding study with ACTICIDE® OIT

Sectio	on A6.4.1-01	Subchronic toxicity (oral)
Annex Point90 days dietary toxicity study in dogsIIA6.4.1		
		 Since no clear effect level (i.e. a LOAEL) could be discerned based on the results of groups 1-4, additional dose levels (groups 5-7) were added in consultation with and at request of the sponsor. Dose levels for groups 5-7 (0, 3000 and 6000 ppm) were selected based on a 14-day range finding study conducted with 3000 and 9000 ppm The high dose of 6000 ppm was eventually lowered to 4500 ppm during treatment based on study results/ethical considerations. 4 RESULTS AND DISCUSSION
4.1	Observations	
4.1.1	Clinical signs	There were no clinical signs evident of toxicity.
4.1.2	Mortality	One female at 4500 ppm was sacrificed on day 30. Inanition was considered to be the cause of the animal's clinical condition.
4.2	Body weight gain	During the first week of treatment at 6000 ppm notable weight loss was recorded for males and females. Body weights remained at approximately the same lower level during the intermittent 4500 ppm treatment (days 14-21), followed by a further reduction at 6000 ppm (days 22-30). Upon commencing treatment at 4500 ppm from day 31 onwards, body weights increased to control levels for males, but body weights of females remained lower throughout treatment (achieving a level of statistical significance on several occasions).
		At 3000 ppm, body weights of females were reduced when compared to control levels essentially from week 4/5 on treatment onwards (achieving statistical significance for lower weight gain on days 50 and 71-92). Body weights of males at 3000 ppm remained similar to control levels.

4.3 Food consumption and compound intake During the first week of treatment at 6000 ppm food consumption was significantly reduced for both males and females. In the intermittent period (days 9-12) when group 7 animals received standard pelleted food, food intake was similar to control levels. Subsequent treatment at 4500 ppm (days 14-21) and 6000 ppm (days 22-30) resulted in a decrease with partial recovery. Upon commencing treatment at 4500 ppm from day 31 onwards, food intake levels recovered to control levels for both males and females.

The average intake of active ingredient (OIT) achieved during the 13week study period was as follows:

Dietary inclusion level	Average OIT intake (mg weight/day)	g OIT/kg body
(ppm)	Males	females
100	1.6	1.6
300	5.5	5.6
1000	22.4	24.7
3000	70.8	87.7

 at the end of treatment; Increased albumin levels for males at 3000 and 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment; Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. 4.5.3 Urinalysis No toxicologically relevant alterations in urinary parameters were noted. 4.6 Sacrifice and pathology 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 	Section A6.4.1-01 Annex Point IIA6.4.1		Point 90 days dietary toxicity study in dogs	
examination 4.5 Blood analysis 4.5.1 Haematology No toxicologically relevant alterations were noted in haematological parameters. 4.5.2 Clinical chemistry The following statistically significant changes in clinical biochemistry parameters were observed: Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment; Increased albumin levels for males at 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment; Increased albumin/globulin ratio for males at 4500 ppm in week 4 and it meale of treatment. 4.5.3 Urinalysis No toxicologically relevant alterations in urinary parameters were noted. 4.6 Sacrifice and pathology Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Note. 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to 0. 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to Dose levels for these additinand dowere set in consultation with the spon			4500 114.5 135.2	
examination 4.5 Blood analysis 4.5.1 Haematology No toxicologically relevant alterations were noted in haematological parameters. 4.5.2 Clinical chemistry The following statistically significant changes in clinical biochemistry parameters were observed: Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment; Increased albumin levels for males at 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment; Increased albumin levels for males at 4500 ppm in week 4 and it mease at 3000 and 4500 ppm at the end of treatment; Increased albumin levels for males at 4500 ppm in week 4 and it mease at 3000 and 4500 ppm. 4.6.5 Sacrifice and pathology 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to 0. 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with the sponsor, the dose levels for this 90-day were sti in consultation with the sponsor, the dose levels for these additional dose groups were based on a 14-day range finding study meres and were st in consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the bigh dose of 600				
 4.5.1 Haematology No toxicologically relevant alterations were noted in haematological parameters. 4.5.2 Clinical chemistry The following statistically significant changes in clinical biochemistry parameters were observed: Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment; Reduced calcium levels for males at 3000 and 4500 ppm in week 4 and in males at 4500 ppm in week 4 and in males at 4500 ppm in week 4 and at the end of treatment. Increased albumin levels for males at 4500 ppm in week 4 and at the end of treatment. 4.5.3 Urinalysis No toxicologically relevant alterations in urinary parameters were noted. A.6.2 Gross and histopathology 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these obse levels for these additional dose groups were added at a later stage. Dose levels for these additional dose groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study method for the sponsor. The high dose of 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm. In consultation with the sponsor, the childing study method at the spores? "99.8. E C Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. <!--</td--><td>4.4</td><td></td><td>No toxicologically relevant ophthalmoscopic findings were noted.</td>	4.4		No toxicologically relevant ophthalmoscopic findings were noted.	
 4.5.2 Clinical chemistry parameters. The following statistically significant changes in clinical biochemistry parameters were observed: Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment; Reduced total protein and albumin levels for females at 4500 ppm at the end of treatment; Increased albumin levels for males at 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment; Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. 4.5.3 Urinalysis No toxicologically relevant alterations in urinary parameters were noted. 4.6 Sacrifice and pathology A.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Mecropsy: One female at 4500 ppm that was sacrificed on day 30 had an emaciated appearance. Histopathology: No toxicologically significant findings. 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND conclusion based on a 7-day range finding study	4.5	Blood analysis		
parameters were observed: - Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment: - Reduced total protein and albumin levels for females at 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment: - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment: - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Increased albumin/globulin ratio for males at 4500 ppm in week 4 and at the end of treatment. - Materials and mistopathology Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 6 the sponsor one control group and two test substance groups were added	4.5.1	Haematology		
 4.6 Sacrifice and pathology 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Necropsy: One female at 4500 ppm that was sacrificed on day 30 had an emaciated appearance. Histopathology: No toxicologically significant findings. 4.7 Other None. 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels for these additional dose groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study and 4000 ppm. In consultation with the sponsor, the high dose of 6000 ppm was lowered to 4500 ppm during treatment based on study results/ethical considerations. The study was based on the following guidelines: OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. 	4.5.2	Clinical chemistry	 parameters. The following statistically significant changes in clinical biochemistry parameters were observed: Reduced calcium levels and increased chloride levels for females at 3000 and 4500 ppm at the end of treatment; Reduced total protein and albumin levels for females at 4500 ppm at the end of treatment; Increased albumin levels for males at 3000 and 4500 ppm in week 4 and in males at 4500 ppm at the end of treatment; Increased albumin/globulin ratio for males at 4500 ppm in week 4 	
pathology 4.6.1 Organ weights Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Necropsy: One female at 4500 ppm that was sacrificed on day 30 had an emaciated appearance. Histopathology: No toxicologically significant findings. 4.7 Other None. 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods Based on a 7-day range finding study for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels for these additional dose groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a tudy results/ethical considerations. The study was based on the following guidelines: OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988.	4.5.3	Urinalysis	No toxicologically relevant alterations in urinary parameters were noted.	
 at 3000 and 4500 ppm. 4.6.2 Gross and histopathology Necropsy: One female at 4500 ppm that was sacrificed on day 30 had an emaciated appearance. Histopathology: No toxicologically significant findings. 4.7 Other 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study , and were set in consultation with the sponsor at 0, 3000 and 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm was lowered to 4500 ppm during treatment based on study results/ethical considerations. The study was based on the following guidelines: OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non- Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. 	4.6			
histopathology emaciated appearance. Histopathology: No toxicologically significant findings. 4.7 Other None. 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods Based on a 7-day range finding study for and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on the following guidelines: - OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non- Rodents", 1998.	4.6.1	Organ weights	Thymus weight and thymus to body weight ratio was reduced in females at 3000 and 4500 ppm.	
 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Materials and methods 5 APPLICANT'S SUMMARY AND CONCLUSION 5.1 Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on study results/ethical considerations. 6 OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. 7 EC Directive 87/302/EEC, B.27: "90-da	4.6.2			
 5.1 Materials and methods Based on a 7-day range finding study and in consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for these additional dose groups were based on a 14-day range finding study for the sponsor. In consultation with the sponsor, the high dose of 6000 ppm was lowered to 4500 ppm during treatment based on study results/ethical considerations. The study was based on the following guidelines: OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. 	4.7	Other	None.	
methodsconsultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance groups were based on a 14-day range finding studymethodsImage: The sponsor one control group and two test substance group and two test substance the sponsor, the high dose of 6000 ppm was lowered to 4500 ppm during treatment based on study results/ethical considerations.methodsImage: The study was based on the following guidelines: Image: OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non- Rodents", 1998.methodsImage: The Study using Non-rodent species", 1988.			5 APPLICANT'S SUMMARY AND CONCLUSION	
 OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. 	5.1		consultation with the sponsor, the dose levels for this 90-day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels and in consultation with/at request of the sponsor one control group and two test substance groups were added at a later stage. Dose levels for these additional dose groups were based on a 14-day range finding study Constitution , and were set in consultation with the sponsor at 0, 3000 and 6000 ppm. In consultation with the sponsor, the high dose of 6000 ppm was lowered to 4500 ppm during treatment based on study results/ethical considerations.	
			 OECD 409, "Repeated Dose 90-day Oral Toxicity Study in Non-Rodents", 1998. EC Directive 87/302/EEC, B.27: "90-days repeated Oral Dose Study using Non-rodent species", 1988. 	

Beagle dogs received the test substance by dietary intake for at least 90

Section A6.4.1-01 Annex Point IIA6.4.1		Subchronic toxicity (oral)		
		90 days dietary toxicity study in dogs		
		days. One control group and three treated groups were tested, each consisting of 4 males and 4 females. Based on the results obtained at these dose levels, in consultation with the sponsor and based on a range finding study, additional groups at 0, 3000 and 6000 ppm were dosed.		
		Chemical analysis of prepared diets was conducted on a regular basis during the study to assess homogeneity, accuracy and/or stability of preparations.		
		The following parameters were evaluated: clinical signs (daily), body weight (weekly), food consumption (daily), ophthalmoscopic examination (at pretest and end of treatment), clinical pathology (pretest, weeks 4 and end of treatment, and for groups 5 and 7 also in week 2), macroscopy and organ weights at termination. Histopathology was performed on selected tissues from dogs of the control groups (i.e. groups 1 and 5) and the high dose groups (i.e. groups 4 and 7).		
5.2	Results and discussion	Homogeneity and accuracy of diet preparations were considered to be acceptable. Stability of diets over 4 weeks at room temperature was confirmed.		
		The average intake of active ingredient (OIT) achieved during the 13- week study period was as follows-		

Dietary inclusion	Mean analytical accuracy (% of target conc.)	Average OIT intake (mg OIT/kg body weight/day)				
level (ppm)		males	females			
100	50%	1.6	1.6			
300	57%	5.5	5.6			
1000	69%	22.4	24.7			
3000	78%	70.8	87.7			
4500 ²	86%	114.5	135.2			

² Between days 1-8 and 22-30 animals received 6000 ppm diets. Between days 14-21 and from day 31 onwards, animals received 4500 ppm diets. From days 9-12 animals received standard dog maintenance pelleted food with canned food. Mean analytical accuracy was 84% for 6000 ppm diet preparations.

It was concluded that the lower recoveries were most likely due to reaction of OIT with sulfur containing compounds in the diet and/or effects of irreversible binding of OIT. Extraction was however complete with regard to the extractable OIT.

One female at 4500 ppm was sacrificed in week 5. Inanition (evidenced by an emaciated appearance at necropsy) was considered to be the cause of the animal's clinical condition.

No mortality occurred at dosages up to 3000 ppm.

Sectio	on A6.4.1-01	Subchronic toxicity (oral)	
Annex IIA6.4.		90 days dietary toxicity study in dogs	
		The lower body weight and food intake at 3000 and 4500 ppm frequently occurred with food scatter observed throughout treatment at these dose levels. There were no clinical signs evident of toxicity up to the highest dose level tested, and there was no morphological indication of organ toxicity. Also, no toxicologically significant haematological alterations or histopathological abnormalities were noted up to 4500 ppm. Therefore, the lower food intake/body weight was considered to be related to palatability of the test diet, rather than being indicative of primary systemic toxicity.	
		Changes in clinical biochemistry parameters noted during treatment in animals at 3000 and 4500 ppm had no morphological correlates and were of a slight nature. These changes consisted of a.o. reduced total protein and albumin levels which are in line with the expected biochemistry changes in case of reduced body weights/food intake. Reduced thymus weights of females at 3000 and 4500 ppm were not supported by any histopathological evidence of organ dysfunction. These changes were therefore considered to be related to the lower body weights and food intake. No toxicological relevance was ascribed to these alterations.	
		It is concluded that at 3000-4500 ppm the maximum tolerated dose has been approximated with regard to palatability of the test diet. It is considered that the level at which signs of primary toxicity would emerge occurs beyond the level of palatability of the test substance.	
5.3	Conclusion		
5.3.1	LO(A)EL	Not applicable.	
5.3.2	NO(A)EL	4500 ppm (3870 ppm based on overall analytical accuracy of the 4500 ppm diet preparations), corresponding to an actual intake of 133 and 157 mg active ingredient (OIT)/kg body weight/day for males and females respectively (115 and 135 mg active ingredient (OIT)/kg body weight/day for males and females respectively, based on overall analytical accuracy of the 4500 ppm diet preparations).	
5.3.3	Other	Since no evidence of target organ toxicity was obtained with any of the examined parameters in this study, the observed effects were considered to be related to palatability of the test diets.	
5.3.4	Reliability	1	
5.3.5	Deficiencies	There were no deviations from the test guidelines/protocol that were considered to have adversely affected the study integrity.	
		Evaluation by Competent Authorities	

EVALUATION BY RAPPORTEUR MEMBER STATE

Use separate "evaluation boxes" to provide transparency as to the

Date

01/04/2009

comments and views submitted

Materials and Methods

Section A6.4.1-01 Annex Point IIA6.4.1	Subchronic toxicity (oral) 90 days dietary toxicity study in dogs
Results and discussion	
Conclusion	
Reliability	1
Acceptability	Acceptable
Remarks	In agreement with the applicant's assessment.
	COMMENTS FROM (specify)
Date	Give date of comments submitted
Materials and Methods	Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state
Results and discussion	Discuss if deviating from view of rapporteur member state
Conclusion	Discuss if deviating from view of rapporteur member state
Reliability	Discuss if deviating from view of rapporteur member state
Acceptability	Discuss if deviating from view of rapporteur member state
Remarks	

Table A6_4-1. Results of clinical chemistry, haematology and urinalysis

parameter changed	Unit	Contro	ol		100 pp	m		300 pp	m		1000 p	pm	
weeks after start of treatment		4		13	4		13	4		13	4		13
males													
No effects													
females													
No effects													

parameter changed	Unit	Control			3000 ppm	4500 ppm			
weeks after start of treatment		2	4	13	4	13	2	4	13
males									
Albumin					↑ * +12%			↑ * +13%	↑ * +9%
Albumin/Globul in ratio								↑ +20%	↑* +30%
females									
Calcium						↓* -4%			↓* -8%
Chloride						↑ * +4%			↑ * +3%
Total protein									↓* -12%
Albumin									↓* -9%

* p < 0,05

Parameter	Contr			low dose		medium dose		lose	
			100 pp	om	300 pp	om	1500 j	1500 ppm	
	m	f	m	f	m	f	m	f	
number of animals examined	4	4	4	4	4	4	4	4	
Mortality	0	0	0	0	0	0	0	0	
clinical signs	=	=	=	=	=	=	=	=	
body weight	=	=	=	=	=	=	=	=	
food consumption	=	=	=	=	=	=	=	=	
clinical chemistry	2	2	2	2	2	2	2	2	
haematology	=	=	=	=	=	=	=	=	
urinalysis	=	=	=	=	=	=	=	=	
gross pathology	=	=	=	=	=	=	=	=	
microscopic pathology	=	=	=	=	=	=	=	=	

¹ Based on all groups, i.e. groups 1-7.

² See Table A6_4-1. Results of clinical chemistry, haematology and urinalysis.

= No toxicologically significant change/incidence similar to control group.

Parameter	3000 ppm		4500 ppn	n	dose- response +/- ¹	
	m	f	m	f	m	f
number of animals examined	4	4	4	4	4	4
Mortality	0	0	0	1	-	-
clinical signs	=	=	=	=	-	-
body weight	=	↓ ²	↓ ²	↓ ²	+	+
food consumption	=	=	↓ 3	↓ 3	+	+
clinical chemistry	4	4	4	4	4	4
haematology	=	=	=	=	-	-
urinalysis	=	=	=	=	-	-
<u>Thymus</u>						
organ weight	=	↓ -46%	=	↓-51%	-	+
gross pathology	=	=	=	=	-	-
microscopic pathology	=	=	=	=		-
Other						
gross pathology Emaciated appearance	0	0	0	1	-	+

¹Based on all groups, i.e. groups 1-7.

² See 4.2

³ See 4.3

⁴ See Table A6_4-1. Results of clinical chemistry, haematology and urinalysis.

= No toxicologically significant change/incidence similar to control group.

Section A6.4.1-02	Subchronic toxicity (oral)
Annex Point IIA6.4.1	90 days dietary toxicity study in rats

		6 REFERENCE	Official use only
6.1	Reference	2007, 90-Day dietary toxicity study with ACTICIDE [®] OIT (2-n-Octyl-4-isothiazolin-3-one) in the rat, unpublished	
6.2	Data protection	Yes	
6.2.1	Data owner	THOR GmbH, Germany	
6.2.2			
6.2.3	Criteria for data protection	Data submitted on existing A.S. for the purpose of its entry into Annex I.	
		7 GUIDELINES AND QUALITY ASSURANCE	
7.1	Guideline study	Yes	

Sectio	n A6.4.1-02	Subchronic toxicity (oral)					
Annex IIA6.4.		90 days dietary toxicity study in rats					
		OECD Guideline no. 408, 1998					
		EPA Health Effects Test Guidelines (OPPTS 870.3100), 1998					
		EC Directive 2001/59/EC, Part B: No. L 225, 2001					
7.2	GLP	Yes					
7.3	Deviations	Yes					
		 Inadvertently, no brain weight was recorded from animal no. 35 (group 4). 					
		Evaluation: sufficient organ weight data were available for adequate interpretation of the study results.					
		 Inadvertently, no clinical signs were recorded on day 64 (groups 5-6). 					
		Evaluation: Sufficient clinical observations were performed for adequate interpretation of the study results.					
		8 MATERIALS AND METHODS					
8.1	Test material	As given in section 2					
8.1.1	Lot/Batch number	Acticide® OIT					
8.1.2	Specification	Technical grade					
8.1.2.1	Description	Amber solid to liquid depending on ambient temperature					
8.1.2.2	Purity						
8.1.2.3	Stability	Stable					
8.2	Test Animals						
8.2.1	Species	rat					
8.2.2	Strain						
8.2.3	Source						
8.2.4	Sex	Male and female					
8.2.5	Age/weight at study initiation	Approximately 6 weeks					
8.2.6	Number of animals per group	10					
8.2.7	Control animals	Yes					
8.3	Administration/ Exposure	Oral					
8.3.1	Duration of treatment	At least 90 days					
8.3.2	Frequency of exposure	daily					
8.3.3	Postexposure period	none					
8.3.4	<u>Oral</u>						

Section A6.4.1-02

Subchronic toxicity (oral)

90 days dietary toxicity study in rats

Annex Point	
IIA6.4.1	

8.3.4.1 Type 8.3.4.2 Dose

Group	Dose Level	Test article intake (mg test substance/kg body weight/day) ¹			
	ppm	ppm males		females	
1	0		0		0
2	100		6		8
3	300		<i>19</i>		23
4	1000		68		82
5	0		0		0
6	3000		210		257

(groups 1-4).

food consumption per day: ad libitum

8.3.4.3	Vehicle	Not applicable
8.3.4.4	Concentration in vehicle	Not applicable
8.3.4.5	Total volume applied	Not applicable
8.3.4.6	Controls	plain diet
8.4	Examinations	
8.4.1	Observations	
8.4.1.1	Clinical signs	Yes, at least once daily
8.4.1.2	Mortality	Yes, at least twice daily.
8.4.2	Body weight	Yes, weekly and on the day preceding the first necropsy date
8.4.3	Food consumption	Yes, weekly.
		Food scatter for groups 1-4 was determined on a daily basis from week 2 onwards. Actual food intake levels were corrected for this food scatter. Food intake of groups 1-4 in week 1 was based on the mean total food scatter determined per group and sex in week 2. For groups 5 and 6, food scatter could not be quantified due to the type of housing (i.e. Macrolon cages containing sawdust as bedding material).
8.4.4	Water consumption	no
8.4.5	Ophthalmoscopic examination	Yes
		at Pre-test : All animals (including spare animals) at week 13: Groups 1, 4, 5 and 6
8.4.6	Haematology	yes
0.1.0	Thematology	Week 13: all animals.
		Erythrocytes count, haemoglobin, Haematocrit, Mean corpuscular

Section A6.4.1-02		Subchronic toxicity (oral)				
Annex IIA6.4		90 days dietary toxicity stud	y in rats			
		volume, Mean corpuscular haemoglobin, Mean corpuscular haemoglobin concentration, Platelet count, Red cell distribution width, Total leucocytes count, Differential leucocyte count, Prothrombin time, Partial thromboplastin time				
8.4.7	Clinical Chemisty	yes Week 13: all animals. Alanine aminotransferase, Alkaline phosphatase, Aspartate aminotransferase, Bilirubin, total, Chloride, Cholesterol, total, Creatinine, Glucose, Phosphorus, Protein, total, Protein, albumin Urea, Calcium, Potassium, Sodium				
8.4.8	Urinalysis	No				
8.5	Sacrifice and pathology					
8.5.1	Organ Weights	yes organs: Adrenal glands, Ovaries, Brain, Spleen, Epididymides, Testes, Heart, Thymus, Kidneys, Uterus, Liver				
8.5.2 Gross and histopathology			ollected at the scheduled sacrifice from all nd the highest dose group (i.e. groups 1, 4, 5			
		Identification marks: not processed	Pancreas			
		Adrenal glands	Peyer's patches (jejunum, ileum) if detectable			
		Aorta	Pituitary gland			
		Brain (cerebellum, mid-brain, cortex)	(Preputial gland)			
		Caecum	Prostate gland			
		Cervix	Rectum			
		(Clitoral gland)	Salivary glands - mandibular, sublingual			
		Colon	Sciatic nerve			
		Duodenum	(Seminal vesicles)			
		Epididymides	(Skeletal muscle)			
		(Eyes with optic nerve and Harderian gland)	(Skin)			
		Female mammary gland area	Spinal cord -cervical, midthoracic, lumbar			
		(Femur including joint)	Spleen			
		Heart	Sternum with bone marrow			
		Ileum	Stomach			
		Jejunum	Testes			
		Kidneys	Thymus			

Section A6.4.1-02	
-------------------	--

Subchronic toxicity (oral)

90 days dietary toxicity study in rats

Annex Point
IIA6.4.1

8.5.3 8.5.4 **8.6**

9.1 9.1.1

9.1.2

9.2

9.3

	(Larynx)	Thyroid including parathyroid			
	(Lacrimal gland, exorbital)	(Tongue)			
	Liver	Trachea			
	Lung, infused with formalin	Urinary bladder			
	Lymph nodes - mandibular, mesenteric	Uterus			
	(Nasopharynx)	Vagina			
	Oesophagus	All gross lesions			
	Ovaries				
	Tissues mentioned within brackets we signs of toxicity or target organ involved to the second state of the	ere not examined microscopically as there were no vement.			
Other examinations	None.				
Statistics	None.				
Further remarks	Dose levels for groups 1-4 (0, 100, 300 and 1000 ppm) were based on results of a 14-day dietary range finding study with ACTICIDE® OIT In this 14-day range finder dose levels were selected to be 0, 2000, 6000 and 10.000 ppm. A dose level of 2000 ppm resulted in an irregular surface of the forestomach in most animals. At 6000 and 10.000 ppm all				
	animals were sacrificed or died spontaneously. Dose levels for groups 5-6 (0 and 3000 ppm) were added and the second sec				
	9 RESULTS AND DIS	SCUSSION			
Observations					
Clinical signs	Hunched posture, abdominal s in most males and all females	swelling and/or piloerection were observed at 3000 ppm in weeks 1/2.			
Mortality	One female at 3000 ppm was a could not be established histor	found dead on day 76. A cause of death pathologically.			
Body weight gain	ppm from week 1 of treatment significance in all instances. S weight gain were also recorde onwards, but did not achieve a weight gain deficit was approx	s reduced for males and females at 3000 t onwards, achieving a level of statistical dightly reduced body weights and body d for females at 1000 ppm from week 5 a level of statistical significance. The total ximately 12% for the 1000 ppm group and a 3000 ppm group, when compared to its			
Food consumption and compound	No toxicologically relevant ch allowance for body weight we	anges in food intake before or after ere observed.			
intake	The average intake of active in week study period is given be	ngredient (OIT) achieved during the 13- low.			
	Average OIT intal	ke (mg OIT/kg body weight/day)*			

Section A6.4.1-02

Subchronic toxicity (oral)

90 days dietary toxicity study in rats

Annex Point IIA6.4.1

100	ppm	300 ppm		1000 ppm		3000 ppm		
М	F	М	F	М	F	М	F	
2	3	9	11	46	56	195	2 39	

* I.e. corrected for for food scatter. Values in italics represent values after correction for mean analytical accuracy.

		represent values after correction for mean analytical accuracy.
9.4	Ophthalmoscopic examination	No abnormalities.
9.5	Blood analysis	
9.5.1	Haematology	no effects
9.5.2	Clinical chemistry	no effects
9.5.3	Urinalysis	Not applicable.
9.6	Sacrifice and pathology	
9.6.1	Organ weights	no effects
9.6.2	Gross and histopathology	Necropsy: Irregular surface of the forestomach and/or a thickened limiting ride of the stomach was observed in all males and 8/10 females at 3000 ppm.
		Histopathology
		Hyperplasia/hyperkeratosis of the squamous epithelium of the forestomach was recorded in all males at 3000 ppm (one male: minimal, eight males: slight and one male: moderate).
		In nine females of group 6 hyperplasia/hyperkeratosis of the squamous epithelium of the forestomach was recorded (one female: minimal, seven females: slight and one female: moderate).
9. 7	Other	None.

10 APPLICANT'S SUMMARY AND CONCLUSION

10.1	Materials and methods	Based on a 14-day dietary range finding study , the dose levels for this 90- day dietary study were selected to be 0, 100, 300 and 1000 ppm. Based on the results obtained at these dose levels , additional groups at 0 and 3000 ppm were dosed.
		 The study was based on the following guidelines. EC Directive 67/548/EEC, B Repeated Dose (90 days) Toxicity (oral), 2001. OECD 408, Repeated Dose 90-day Oral Toxicity Study in Rodents, 1998.

- EPA 712-C-98-199, 90-Day Oral Toxicity in Rodents, 1998.

Section A6.4.1-02		Subchronic toxicity (oral)					
Annex IIA6.4		90 days dietary toxicity study in rats					
inclusion analytical body weight/day) ¹		least 90 days. One each consisting of obtained at these of additional groups The following par Clinical signs, fur and ophthalmosco organ weights and Homogeneity and to be acceptable. S temperature was of The average intak week study period	e control group an f 10 males and 10 dose levels and in at 0 or 3000 ppm rameters were eva actional observation opy. At termination a histopathology of accuracy of diet p Stability of diets of confirmed.	d three treated females. Base consultation v were dosed. luated: ons, body weig n: clinical path on a selection of preparations w over 6 weeks a	d groups were tested, ed on the results with the sponsor, ght, food consumption hology, macroscopy, of tissues. were considered t room		
		T intake (mg OIT/kg t/day) ¹					
		level (ppm)	accuracy (% of target conc.)	males	females		
		100	40	2	3		

49

61

93

represent values after correction for mean analytical accuracy.

300

1000

3000

¹ Le. corrected

² No quantitative assessment of food scatter could be performed due to the type of housing. Based on food scatter measurements at the 1000 ppm level, actual food intake and test article intake at the 3000 ppm level was considered to be at least 15% less than indicated in the table.

9

46

for food scatter.

195²

11

56

239 ²

Values in italics

It was concluded that the lower recoveries were most likely due to reaction of OIT with sulfur containing compounds in the diet and/or effects of irreversible binding of OIT. Extraction was however complete with regard to the extractable OIT.

Histopathological assessment revealed hyperplasia/hyperkeratosis of the squamous epithelium of the forestomach in most animals at 3000 ppm which correlated to thickening of the limiting ridge and irregular surface of the forestomach. These morphological changes were considered to represent a response to local irritation to test material residing in the forestomach. There were no histological changes apparent in tissues and organs other that the stomach.

The lower body weights (total weight gain deficit approximated 20%) and clinical signs consisting of hunched posture, abdominal swelling and/or piloerection at 3000 ppm were considered to be related to the stomach effects.

Section A6.4.1-02		Subchronic toxicity (oral)				
Annex IIA6.4.		90 days dietary toxicity study in rats				
		From the parameters assessed, no evidence for neurotoxic potential of the test substance was obtained.				
		No treatment-related mortality, and no effects on functional observations tests, food consumption, clinical pathology and organ weights occurred at any of the dose levels administered. Also, no clinical signs of toxicity, effects on body weight, macro- or microscopic abnormalities were apparent at dose levels up to 1000 ppm.				
10.3	Conclusion					
10.3.1	LO(A)EL	Local toxicity: 3000 ppm (critical effects: hyperplasia/hyperkeratosis of the squamous epithelium of the forestomach (all males and 9/10 females), thickening of the limiting ridge and irregular surface of the forestomach (all males and 8/10 females).				
10.3.2	NO(A)EL	 Local toxicity: 1000 ppm (610 ppm based on overall analytical accuracy of the 1000 ppm diet preparations), corresponding to an actual intake of 68 and 82 mg active ingredient (OIT)/kg body weight/day for males and females respectively (46 and 56 mg active ingredient (OIT)/kg body weight/day for males and females respectively, based on overall analytical accuracy of the 1000 ppm diet preparations). Systemic toxicity: 3000 ppm (2790 ppm based on overall analytical accuracy of the 3000 ppm diet preparations), corresponding to an actual intake of 210 and 257 mg active ingredient (OIT)/kg body weight/day for males and females respectively (195 and 239 mg active ingredient (OIT)/kg body weight/day for males and females respectively, based on overall analytical accuracy and females respectively (195 and 239 mg active ingredient (OIT)/kg body weight/day for males and females respectively, based on overall analytical accuracy of the 3000 ppm diet preparations). 				
10.3.3	Other	Evidence for primary systemic toxicity was absent at dose levels up to 3000 ppm.				
10.3.4	Reliability	1				
10.3.5	Deficiencies	Yes: any deviations from the protocol/test guideline were considered to have no adverse effect on the study integrity (see 2.3).				

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	01/04/2009
Materials and Methods	
Results and discussion	
Conclusion	
Reliability	1
Acceptability	Acceptable

Section A6.4.1-02	Subchronic toxicity (oral) 90 days dietary toxicity study in rats					
Annex Point IIA6.4.1						
Remarks	In agreement with the applicants assessment					
	COMMENTS FROM (specify)					
Date	Give date of comments submitted					
Materials and Methods	Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state					
Results and discussion	Discuss if deviating from view of rapporteur member state					
Conclusion	Discuss if deviating from view of rapporteur member state					
Reliability	Discuss if deviating from view of rapporteur member state					
Acceptability	Discuss if deviating from view of rapporteur member state					
Remarks						

Table A6_4 1. Results of clinical chemistry haematology and urinalysis

<mark>parameter</mark> changed	<mark>Unit</mark>	Contro	Controls		l ow dose me		medium dose		<mark>high dose</mark>				
<mark>weeks after start</mark> <mark>of treatment</mark>													
males													
No effects													
<mark>females</mark>													
No effects													

Parameter	Contr	ol	low do	se	mediu	edium dose high dose		lose	
			100 pp	100 ppm 300 pp		om	1000 j	1000 ppm	
	m	f	m	f	m	f	m	f	
number of animals examined	10	10	10	10	10	10	10	10	
Mortality	0	0	0	0	0	0	0	0	
clinical signs	0	0	0	0	0	0	0	0	
body weight ²	=	=	=	=	=	=	=	↓ (-18%)	
food consumption	=	=	=	=	=	=	=	=	
clinical chemistry	=	=	=	=	=	=	=	=	
haematology	=	=	=	=	=	=	=	=	
<u>Stomach</u>									
organ weight	NA	NA	NA	NA	NA	NA	NA	NA	
gross pathology	=	=	=	=	=	=	=	=	
microscopic pathology	=	=	=	=	=	=	=	=	

Table A6_4-2. Results (specify) of repeated dose toxicity study

¹ Based on all groups, i.e. groups 1-6.

² Total weight gain deficit over the study period compared to control weight gain given between parentheses.

NA Not applicable.

Table A6_4-2. (Continued)

Parameter	Control		3000 ррт		dose- response +/- ¹	
	m	f	m	f	m	f
number of animals examined	10	10	10	10	10	10
Mortality	0	0	0	1	-	-
clinical signs Hunched posture, abdominal swelling and/or piloerection	0	0	7	10	+	+
body weight ²	=	=	↓ (-14%)	↓ (-17%)	+	+
food consumption	=	=	=	=	-	-
clinical chemistry	=	=	=	=	-	-
haematology	=	=	=	=	-	-
Stomach						
organ weight	NA	NA	NA	NA	NA	NA
gross pathology Irregular surface of the forestomach and thickened limiting ride of the stomach	0	0	10	8	+	+
microscopic pathology Hyperplasia/hyperkerato sis of the squamous epithelium of the forestomach	0	0	10	9	+	+

1 Based on all groups, i.e. groups 1-6.

2 Total weight gain deficit over the study period compared to control weight gain given between parentheses.

NA Not applicable.

Section A 6.4.2-01

Annex Point	
IIA6.3 / 6.4 / 6.5	

Repeated dose toxicity 90-day dermal toxicity study in rats

Official use only 11 REFERENCE 11.1 Reference 1995, n-Octylisothiazolinone (OIT) 94% +/- 3%: 90-Day Dermal Subchronic Toxicity Study in the Rat, unpublished 11.2 Yes **Data protection** 11.2.1 Data owner THOR GmbH, Germany 11.2.2 11.2.3 Criteria for data Data submitted on existing A.S. for the purpose of its entry into Annex protection I.

Annex	n A 6.4.2-01 Point / 6.4 / 6.5	Repeated dose toxicity 90-day dermal toxicity study in rats				
		12 GUIDELINES AND QUALITY ASSURANCE				
12.1	Guideline study	Yes. EPA 82-3 which equals OECD 411				
12.2	GLP	Yes				
12.3	Deviations	No				
		13 MATERIALS AND METHODS				
13.1	Test material	As given in section 2				
	Lot/Batch number					
13.1.2		Technical grade				
	Description	Brown yellow liquid				
13.1.2.2	2 Purity		x			
13.1.2.3	3 Stability					
13.2	Test Animals					
13.2.1	Species	Rat				
13.2.2	Strain					
13.2.3	Source					
13.2.4	Sex	Both				
13.2.5	Age/weight at study initiation	5-6 weeks Males: 115-159 g; Females 111-142 g				
13.2.6	Number of animals per group	10 per sex /group				
13.2.7	Control animals	Yes				
13.3	Administration/ Exposure	Dermal				
13.3.1	Duration of treatment	90 days				
13.3.2	Frequency of exposure	Daily				
13.3.3	Postexposure period	No				
13.3.4	<u>Dermal</u>					

Annex	n A 6.4.2-01 Point / 6.4 / 6.5	Repeated dose toxicity 90-day dermal toxicity study in rats	
13.3.4.1	Area covered	5 cm x 7 cm on the back and the flanks of each animal	
13.3.4.2	2 Occlusion	semiocclusive	
13.3.4.3	8 Vehicle	Corn oil	
13.3.4.4	Concentration in vehicle	1:200 (5 mg/kg bw /day); 1:40 (25 mg/kg bw /day); 1:8 (125 mg/kg bw /day)	
13.3.4.5	Total volume applied	1 ml / kg bw	
13.3.4.6	5 Duration of exposure	Other: 6 hours per day	
13.3.4.7	Removal of test substance	water	
13.3.4.8	3 Controls	vehicle	
13.4	Examinations		
13.4.1	Observations		
13.4.1.1	Clinical signs	Yes, once daily	
13.4.1.2	2 Mortality	Yes, twice daily	
13.4.2	Body weight	Yes, weekly	
13.4.3	Food consumption	Yes, twice a week	
13.4.4	Water consumption	No	
13.4.5	Ophthalmoscopic examination	Yes, once pre-dose (all animals) and once during last week of treatment (controls and high dose animals)	
13.4.6	Haematology	Yes, from all animals at end of study; Parameters: Haematocrit, haemoglobin concentration, erythrocyte count, total and differential leukocyte count, platelet count, clotting time, prothrombin time, thromboplastin time	
13.4.7	Clinical Chemisty	Yes, from all animals at end of study;	
		Parameters: sodium, potassium, glucose, total cholesterol, urea, blood urea nitrogen, total bilirubin, creatinine, total protein, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma glutamyl transpeptidase, lipids, glutamate dehydrogenase	
13.4.8	Urinalysis	Yes, from all animals at end of study; Parameters: appearance, volume, osmolality, specific gravity, pH, protein, glucose, blood and other: leukocytes, ketones, bilirubin, urobilinogen, microscopy of centrifuged deposits: cells, organic inorganic components, casts.	
13.5	Sacrifice and pathology		
13.5.1	Organ Weights	yes organs: liver, kidneys, adrenals, testes, epididymides, uterus, ovaries, thymus, spleen, brain, heart and others: pituitary thyroid.	
13.5.2	Gross and histopathology	yes high dose group and controls as well as intercurrent deaths organs: brain, spinal cord, pituitary, thyroid, parathyroid, thymus, 27/44	

Section A 6.4.2-01 Annex Point IIA6.3 / 6.4 / 6.5		Repeated dose toxicity 90-day dermal toxicity study in rats					
13.5.3	Other examinations	Local skin reactions.					
		For scale of evaluation see table A6.3-2 attached to this summary.					
13.5.4	Statistics	Test for homogeneity of variance: Lenvene's test, Bartlett's test (anova) Comparision: Dunnett's two-tailed t-test, Kruskal-Wallis test together with Wilcoxon rank-sum test					
		SAS sofware package 6.04, TERASYS online data collection system					
13.6	Further remarks						

14 RESULTS AND DISCUSSION

(Describe findings. If appropriate, include table. Sample tables are given below.)

14.1	Observations		
14.1.1	Clinical signs	Apart from minimal to slight skin alterations in the intermediate and high dose group being described in section 4.5, there were no clinical changes during the experimental period that could be attributed to treatment with the test article.	
14.1.2	Mortality	In males there were no mortalities throughout the treatment period.	
		In females the following animals died during the treatment period:	
		Group 1 - 0 mg/kg/day - 41 F, was found dead an day 13, replaced by 81 F	
		Group 2 - 5 mg/kg/day - 57 F, was found dead after blood sampling an day 91	
		Group 3 - 25 mg/kg/day - 64 F, was found dead after blood sampling an day 90; - 67 F, was found dead after blood sampling an day 91	
		All mortalities are considered to be unrelated to treatment with the test material.	
14.2	Body weight gain	There was an apparent effect on body weight gain in high dose males (125 mg/kg/day) from the fourth week of study onwards with statistically significant body weight data in weeks 9, 11 to 13 and at necropsy.	
		In consequence, overall body weight change (week 1 to necropsy) was statistically significantly reduced for high dose males.	
		There was no treatment-related effect on body weights at 5 and 25 mg/kg/day.	
		There were no apparent treatment-related effects on body weight in female animals	
14.3	Food consumption and compound intake	There were no signs of treatment-related effects on overall food intake	
14.4	Ophtalmoscopic examination	There were no treatment-related ocular changes.	
14.5	Blood analysis		

Annex	n A 6.4.2-01 Point / 6.4 / 6.5	Repeated dose toxicity 90-day dermal toxicity study in rats	
14.5.1	Haematology	Although statistical evaluations revealed a few minor significantly different changes, there were no treatment-related findings observed at the end of the experimental period.	
14.5.2	Clinical chemistry	Although statistical evaluation revealed a few significantly different minimal changes, there were no treatment-related findings observed at the end of the experimental period.	
		Markedly increased means for GLDH in control males were due to high levels of a single animal, which is considered to be of minor significance. Slightly increased statistically significant AST levels in high dose females are still in the range of our Background data and in the view of no adverse histopathological liver changes, these finding are felt to be of no toxicological significance.	
14.5.3	Urinalysis	There were no treatment-related urine analysis findings at the end of the treatment period.	
14.6	Sacrifice and pathology		
14.6.1	Organ weights	Although statistical evaluation revealed a few significantly different minor changes, there were no treatment-related organ weight changes in treated animals.	
14.6.2	Gross and	MACROSCOPIC NECROPSY FINDINGS	
	histopathology	Apart from minimal to slight skin alterations in the intermediate and high dose group, there were no macroscopic lesions in any of the organs or tissues examined that could be ascribed to the test article.	
		MICROSCOPIC NECROPSY FINDINGS	
		The only microscopic treatment-related findings were lesions in the treated skin sites of high dose males and females. These lesions were squamous cell hyperplasia, sebaceous cell hyperplasia, folliculitis, dermatitis and hemorrhages.	
		There were no histopathological lesions in the other organs and tissues suggestive of systemic target organ toxicity due to the test article.	
		Tissues from low dose and intermediate dose groups were not examined histopathologically.	
14.7	Other	LOCAL SKIN REACTIONS	
		There were no cutaneous lesions in control animals being treated with corn oil and there were no cutaneous lesions in low dose animals receiving 5 mg/kg/day apart from a single occasion in a single female in week 12, when slight atonia was observed. This finding is considered to be of no toxicological significance.	
		Administration of OIT at a dose level of 25 mg/kg/day was relatively well tolerated and elicited only minimal local skin reactions. Overall mean scores (week 2 to 13) revealed the following values: erythema (grade: 0.0 to 0.2 M; 0.0 to 0.3 F; mean: 0.1 M; 0.2 F), edema (grade: 0.0 to 0.3 M; 0.0 to 0.2 F; mean: 0.1 M/F) and atonia (grade: 0.0 to 1.0 M; 0.0 to 0.9 F; mean 0.4 M; 0.3 F).	
		A dose level of 125 mg/kg/day was not well tolerated and elicited slight to moderate skin lesions (overall mean scores, week 2 to 13) such as erythema (grade: 1.3 to 2.1 M; 1.3 to 2.0 F; mean: 1.8 M; 1.6 F), edema (grade: 1.0 to 2.0 M; 1.3 to 2.0 F; mean: 1.8 M/F), atonia (grade: 1.0 to 2.0 M; 1.2 to 2.0 F; mean: 1.8 M/F), desquamation (grade: 0.0 to 2.0 M; 0.0 to 1.4 F; mean: 1.3 M; 0.9 F) and fissures (grade: 0.1 to 0.8 M; 0.0 to 0.7 F; mean: 0.4 M; 0.2 F).	

Sectio	on A 6.4.2-01	Repea	ted d	ose toxi	city		
	Point / 6.4 / 6.5	90-day	dermal	toxicity s	study in r	ats	
		examine	ed (eryi			2 to 13) for the local reactions nia, desquamation and fissures)	are
		Mean to	otal sco	re			
			Gl	G 2	G3	G4	
		males	0.0	0.0	0.1	1.4	
		females	0.0	0.0	0.1	1.2	
						foliation) was observed in the m out the experimental period.	ajority
		15	APPI	JCANT	'S SUMN	IARY AND CONCLUSION	
15.1	Materials and methods	Per-gui	deline	study with	h technico	al grade test item (96.4 % OIT).	
15.2	Results and discussion	Treatment with the test article OIT applied dermally to intact skin sites produced minimal local reactions at the application site in animals receiving 25 mg/kg/day and slight to moderate cutaneous lesions at the high dose levels of 125 mg/kg/day being characterized microscopically as cell hyperplasia, folliculitis, dermatitis and hemorrhages.					
		distinct	ively re		om week	f high dose males exclusively wa t of treatment onwards when con	
						eous reactions in male and fema al at a dose level of 5 mg/kg/day	
		control,	one lo vental p	w dose an procedure	nd two in	oughout the experimental period termediate dose females were du considered to be unrelated to tre	ie to
15.3	Conclusion					lose level of 5 mg/kg/day when kin for at least 90 days.	
		Adminis relative	stration ly well	of the te tolerated	st article	at a dose level of 25 mg/kg/day ted only minor local skin reaction	
		to mode edema, Microso	erate sk atonia, copical	in lesions desquan ly these c	s being de nation, fis utaneous	as not well tolerated and elicited escribed macroscopically as ervi sures and scabbing without exfo lesions were defined as cell is and hemorrhages.	thema,
			-			bited an apparent adverse effect week of study onwards.	t on
15.3.1	LO(A)EL	125 mg/kg/day based on slight to moderate local skin reactions: macroscopically: erythema, edema, atonia, desquamation, fissures and scabbing without exfoliation; microcsopically: cell hyperplasia, folliculitis, dermatitis and hemorrhages; decreased body weight gain in males from 4th week onwards)					
15.3.2	NO(A)EL	25 mg/k	g/day				
15.3.3	Other: local LOAEL	25 mg/k	g/dav				
15.3.4		1	0				
	-						
15.3.5	Deficiencies	No					

Section A 6.4.2-01

Repeated dose toxicity

90-day dermal toxicity study in rats

Annex Point IIA6.3 / 6.4 / 6.5

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	17/04/2009
Materials and Methods	
Results and discussion	
Conclusion	
Reliability	1
Acceptability	Acceptable
Remarks	In agreement with the applicant's assessment.
	COMMENTS FROM (specify)
Date	Give date of comments submitted
Materials and Methods	Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state
Results and discussion	Discuss if deviating from view of rapporteur member state
Conclusion	Discuss if deviating from view of rapporteur member state
Reliability	Discuss if deviating from view of rapporteur member state
Acceptability	Discuss if deviating from view of rapporteur member state
Remarks	

OIT, CAS 26530-20-1

Table A6_3-1. Results of clinical chemistry haematology and urinalysis

(Use this or similar table, if relevant effects occur and if time sequence is important. Give either symbols for increases or decreases (↑↓) or abbreviations inc., dec. Only if more information is needed, give figures or percentages.)

parameter changed	<mark>Unit</mark>	Contro	ls	low do:	<mark>se</mark>	mediun	r dose	<mark>high de</mark>)se	
weeks after start of treatment										
males										
females										

<u>* p < 0,05</u>

Give only those parameters which are changed in at least one dose group compared to control. Usually only statistically significant effects

Depending on number of parameters changed one table each for Haematology, Clinical Chemistry, Urinalysis

Table A6_3-2. Results (cutaneous) of repeated dose toxicity study

APPENDIX I	APPENDIX I (cont.)
SCALE OF EVALUATION OF CUTANEOUS LESIONS <u>Erythema</u> 0 - no erythema 1 - slight erythema (hardly visible) 2 - moderate erythema (well-defined) 3 - severe erythema (purplish-red)	<u>Eschar formation</u> N - no Y - yes <u>Exfoliation</u> (eschar formation) N - no Y - yes
Edema 0 - no edema 1 - slight edema (hardly visible to clearly visible with obvious swelling) 2 - moderate edema (swelling of approximately 1 mm) 3 - severe edema (swelling greater than 1 mm) Atonia (without eschar formation) 0 - normal 1 - slight atonia (modification in elasticity) 2 - moderate atonia (slow return to normal) 3 - marked atonia (no elasticity) Desquamation (without eschar formation) 0 - none 1 - slight desquamation 2 - moderate desquamation (crusts and scales) 3 - pronounced desquamation (marked scaling with bare areas) Fissures 0 - none 1 - slight fissures (cracks in the epidermis) 2 - moderate fissures (cracks with bleeding)	

OIT, CAS 26530-20-1

July, 2007

			cai Skin Reaction welk 1 of atudy			Table 6			Local Skih Reaction		
) Male animals	1					b) Female and	mais				_
		Group 1 O Ing/kg/day	Group 2 5 mg/kg/day	Group 3 25 mg/kg/day	Group 4 125 mg/kg/day			Group 1 O mg/kg/day	Group 2 5 mg/kg/day	Group 3 25 mg/kg/day	Group 4 125 mg/kg/daj
	Mean	0.0	0.0	0.0	0.0	Erythema	Mean SD	0.0			
Erythema	SD N	0.0	0.0 10	0.0	0.0	C. yanna	N	10	10	10	10
	Mean	0.0	0.0	0.0	0.0	Edema	Mean SD	0.0			
Edema	SD N	0.0	0.0	0.0	0.0	Edema	N	10		0.0	0.0
							Mean	0.0			
Atonia	Mean SD	0.0	0.0	0.0	0.0	Atonia	SD	0.0	0.0 fC	0.0	0.0
	N	10	10	10	10	10.000	Mean	0.0	0.0	0.0	00
Desquamation	Mean SD	0.0	0.0	0.0	0.0	Desquamation		0.0	0.0	0.0	0,0
	N	10	10	10	10		Mean	0.0			
-	Mean	0.0	0.0	0.0	0.0	Fissures	SD	0.0	0.0	0.0	0.0
Fissures	SD N	0.0 10	0.0 10	0.0 10	0.0		N	10	10	10	10
Eschar formation %	Incidence	D	٥	0	0	Escher formation %	Incidence	0	0	c	D
						Exfoliation %	Incidence	0	0	0	D
Excollation %	Incidence	a	0	0	D						
		Sector Sector Sector Sector						Come Many Line	al Chin Reaction		
Table 7			cal Skin Reaction			Table 7			eal Skin Reaction		
			cal Skin Reaction eek 2 of study						cal Skin Reaction eek 2 of study		
a) Mais animak	s	Occasion w	eek 2 of study			Table 7 b) Female anima	als	Occasion we	eek 2 of study	Group 3	Group 4
				Group 3 25 mg%g/day	Greup 4 125 mg/kg/day		ais			Group 3 25 mg/kg/day	Group 4 125 mg/kg/day
<u>a) Mais animak</u>	Mean	Occasion w Group 1 O mg/kg/day	Group 2 5 mg/kg/day 0,0	25 mg/kg/day	125 mg/kgiday 2.0	b) Female animi	Mean	Occasion we Group 1 O mg/kg/day 0.0	croup 2 5 mg/Rg/day	25 mg/kg/day	125 mg/kg/day 2.0
	R	Occasion w Group 1 0 mg/kg/day	Group 2 5 mg/kg/day	25 mg/kg/day	125 mg/kg/day			Occasion we Group 1 O mg/kg/day	eek 2 of study Group 2 5 mg/Rg/day	25 mg/kg/day	125 mg/kg/day
a) Male animali Erythema	Mean SD N Mean	Occasion w Group 1 0 mg/kg/day 0.0 10 0.0	Group 2 5 mg/kg/day 0,0 10	25 mg/kg/day 0,0 0,0 10 0,0	125 mg/kg/day 2.0 0.0	b) Female anima Erythema	Mean SD N	Occasion W Group 1 O mg/kgidey 0.0 10 0.0	Group 2 5 mg/kg/day 0.0 10	25 mg/kg/day 0.0 10	2.0 2.0 10 2.0
a) Male animali Erythema	Mean SD N	Group 1 Group 1 0 mg/kg/day 0,0 10	Group 2 5 mg/kg/day 0.0 10	25 mg/kg/day 0.0 0.0 10	125 mg/kg/day 2.0 0.0 10	b) Female animi	Mean SD N	Occasion w Group 1 O mg/kg/day D.D 0.0 10	Group 2 5 mg/Rg/day 0.0 10	25 mg/kg/day 0.0 10	2.0 0.0 10
<u>a) Mais animak</u>	Mean SD N Mean SD N	Occasion w Group 1 0 mg/kg/day 0.0 0.0 10 0.0 10 10	Group 2 5 mg/kg/day 0.0 10 0.0 10	25 mg/kg/day 0,0 0,0 10 0,0 0,0 10	125 mg/kg/day 2.0 0.0 10 2.0 0.0 10	b) Female anima Erythema	Mean SD N Mean SD	Occasion w Group 1 0 mg/kg/day 0.0 10 10	Group 2 5 mg/Rgday 0.0 10 0.0 0.0	25 mg/kg/day 0,0 0,0 10 0,0	20 0.0 10 2.0 0.0 10 2.0 0.0 10
a) <u>Male animali</u> Erythema Edema	Mean SD N Mean SD	Occasion w Grexup 1 0 mg/kg/day 0.0 10 0.0 10 0.0 0.0 10 0.0 0.0 0.0 0.	Caroup 2 5 mg/kg/day 0,0 0,0 10 0,0 10 0,0 0,0 0,0 0,0 0,0 0	25 mg/kg/day 0.0 0.0 10 0.0 10 0.0 10 0.1 0.3	125 mg/kg/day 20 00 10 20 00 10 20 00	b) Female anima Erythema	Mean SO N Mean SD N	Cocasion w Group 1 0 mg/kg/dey 0.0 10 0.0 10 0.0 0.0 10	Group 2 5 mg/kg/day 0.0 0.0 10 0.0 0.0 10	25 mg/kg/day 0.0 10 0.0 10	20 0.0 10 2.0 0.0 10
a) <u>Male animali</u> Erythema Edema	Mean SD N SD N Mean SD N	Occasion w Group 1 0 mg/kg/day 0.0 10 0.0 0.0 0.0 0.0 0.0 10 10	eek 2 of study Group 2 5 mg/kg/day 0,0 0,0 10 0,0 0,0 0,0 0,0 10	25 mg/kg/day 0.0 10 0.0 10 0.0 10 0.0 10 0.1 0.1 0.3 10	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10	b) Female avim Erythema Edame	Mean SD N SD SD N Mean SD N	Cccasion w Group 1 0 mg/kgdey 0.0 0.0 10 0.0 0.0 0.0 0.0 10 0.0 10 10	Croup 2 5 mg/Rg/day 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10	25 mg/kg/day 0.0 10 0.0 0.0 10 0.0 10 0.0 10 0.1 0.3 10	125 mg/kg/kg/ 20 0,0 10 2,0 0,0 10 2,0 0,0 10 2,0 0,0 10
a) Male animali Erytheme Edema Atonia	Mean SD N SD N Mean SD	Croup 1 0 mg/kg/day 0 mg/kg/day 10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10 0.0 0.	Caroup 2 5 mg/kg/day 0,0 0,0 10 0,0 10 0,0 0,0 0,0 0,0 0,0 0	25 mg/kg/day 0.0 0.0 10 0.0 10 0.0 10 0.1 0.3	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10	b) Female avim Erythema Edame	Mean SD N SD N Mean SD N Mean SD	0ccasion w 0 mg/kg/day 0 mg/kg/day 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Croup 2 5 mg/tg/dw/ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	25 mp/kg/dky 00 00 10 00 10 00 10 10 10 01 10 00 00	125 mg/kg/kg/ 20 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 0.0 0.0
a) Male animali Erytheme Edema Atonia	Mean SD N SD SD N Mean SD N Mean	Occasion w Greup 1 0 mg/kg/day 00 10 0.0 0.0 10 0.0 10 0.0 0.0 10 0.0 10 0.0 0.	eek 2 of study Group 2 5 mg/sp/day 0,0 0,0 10 0,0 0,0 10 0,0 0,0 10 0,0 0,	25 mg/kg/day 0,0 0,0 10 0,0 10 0,0 10 0,1 0,3 10 0,0 0,0	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10	b) Fertale avinu Erythema Edeme Atonia	Mean SD N Mean SD N Mean Mean	0ccasion w 0 mg/kg/day 0 0 mg/kg/day 0 0 0 0 10 0 0 0 0 10 0 0 0 0 10 0 0 0	Group 2 5 mg/kg/day 00 00 10 00 00 00 00 00 00 00 00 00 00	25 mg/kg/day 0.0 10 0.0 10 0.0 10 10 0.0 10 0.0 10 0.0 10 0.0 0.	125 mg/kg/day 2,0 0,0 10 2,0 0,0 10 2,0 0,0 10 2,0 0,0 10 0,0 10
a) <u>Mala animal</u> Erythema Edema Atonia Desquiimation	Mean SD N Mean SD N Mean SD N Mean	Occasion w Group 1 0 mg/kg/day 0.0 10 0.0 0.0 0.0 0.0 0.0 10 0.0 0.0 0	eek 2 of study Group 2 5 mg/sp/day 0,0 0,0 10 0,0 0,0 0,0 0,0 0,0	25 mg/kgrday 0.0 0.0 10 0.0 10 0.1 0.3 10 0.0 10 0.0 10 0.0 0.0	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	b) Fertale avinu Erythema Edeme Atonia	Mean SD N Mean SD N Mean SD N Mean SD N	Cccasion with Croup 1 Omg/kg/day 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 0.	Group 2 SmgRg/day 0.0 <	25 mg/kg/dg/ 0,0 0,0 10 0,0 0,0 10 10 10 0,0 10 0,0 10 0,0 0,	128 mg/kg/day 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 0.0 0.
a) Maik animali Erythema Edema Atonia	Mean SD N Wean SD N SD N Mean SD N	Creup 1 0 mg/kg/day 0 mg/kg/day 10 0.0 10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	eek 2 of study Group 2 5 mg/sgridsy 10 0.0 0.0 0.0 0.0 0.0 0.0 10 0.0 0.0 0	25 mg/kgrday 0.0 0.0 10 0.0 0.0 0.0 0.1 0.1 0.1 0.1	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 0.0 0.0 0.0 10	b) Temale avinu Etythema Edema Atonia Desquamation	Mean SD N Mean SD N Mean SD N SD N	Cccasion we Group 1 O mg/kp/day 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10	Group 2 SmgRg/day 0.0 <	25 mg/kg/dgy 00 00 10 00 00 00 00 10 10 00 00 10 00 0	125 mg/kg/day 2,0 0,0 10 2,0 0,0 10 2,0 0,0 10 2,0 0,0 10 0,0 10
a) <u>Mala animal</u> Erythema Edema Atonia Desquiimation	Mean SD N SO N Mean SO N Mean SO N Mean SD	Group 1 0.0 0 mg/kg/day 0.0 10 0.0 0.0 0.0 10 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	eek 2 of study Group 2 Singkgy/day 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	25 mg/kgrday 0.0 0.0 0.0 10 0.0 10 0.1 0.1 0.1 0.1 0	125 mg/kg/dey 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 0.0 0.0 0.0 0.0 0.0 0.	b) Temale avinu Etythema Edema Atonia Desquamation	Mean SD N SD N Mean SD N N SD SD SD	Cccasion with Croup 1 Omg/kg/day 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 10 0.0 0.	Group 2 SmgRg/day 0.0 <	25 mg/kg/tgy 00 00 10 00 10 00 10 10 01 01 03 10 00 00 00 00 00 00 00 00 00 00 00 00	128 mg/kg/day 2.0 0.0 10 2.0 0.0 10 2.0 0.0 10 0.0 0.


OIT, CAS 26530-20-1

July, 2007


			xeal Skin Reaction week 6 of study	_		Table 11			xal Skin Reaction		and the second s
a) Male animale						<u>b</u>) Female anim	als				
		Group 1 Dimg/kg/day	Group 2 5 mg/kg/day	Group 3 25 mg/kg/day	Group 4 125 mg/kg/day			Group 1 0 mg/kg/day	Group 2 5 mg/kgiday	Group 3 25 mg/kg/da	Group 4 ny 125 mg/kg
Erythema	Mean? SD	0.0	0.0	0.1	1.7		Mean	0.0	0.0		.0
	N	10	10	10	10	Erythema	SD N	0.0	0.0		0
Edema	Mean SD	0.0	0.0	0.1 0.3	1.4 0.5		Mean	0.0	0.0	0.	.1
	N	10	10	10	10	Edema	SD N	0.0	0.0	0	3
Atonia	Mean SD	0.0 0.0	0.0 0.0	0.3	1.3 0.5		Mean	0.0	0.0	0	.0
	N	10	10	10	10	Atonia	SD N	0.0	0,0	0.1	0
Descustoria	Mean SD	0.0	0.0	0.0	0.8						
Desquarnation	N	10	0.0	0.0 10	0.4	Desquamation	Mean SD N	0.0 0.0 10	0,0 0,0 10	0.	0
	Mean	0.0	0.0	0.0	0.7						
Fissures	SD N	0.0	0.0	0.0	0.5	Fissures	Mean SD	0.0	9.0 0.0	σ.	0
Eschar							N	10	10	1	°
lormation %	Incidence	٥	0	0	100	Eschar formation %	Incidence	Ø	o	,	a i
Extellation %	Incidence	0	D	0							
Table 18		Group Mean Loc	cal Skin Reaction	ŭ	0	Exteriation %	Incligence	0 Group Mean Loca			
Table 18 a) Male strimats		Group Mean Loc	cal Skim Reaction neak 13 of study					Group Mean Loca Depasion was	/ Skin Reaction k 13 of study		
		Group Mean Loc	cal Skin Reaction	Group 3 25 mg/kg/day	0 Group 4 125 mg/kgday	Table 18		Group Mean Loca	I Skin Reaction	Group 3 25 mp Kgriday	g Group 4 125 mg/kg/day
a <u>) Maie anima'a</u>	Mean	Group Mean Loc Occasion w Group 1 O mg/kgiday 0.0	cal Skim Reaction eek 13 of study Group 2 5 mg/rg/day 0.0	Group 3 25 mg/kp/day 0.2	Group 4 125 mg/kg/day 2.1	Table 18 <u>(b) Ferrate anim</u>	Meen SD	Group Mean Loca Decasion was Group 1 <i>D mg</i> kg/day 0.0	I Skin Reaction ik 13 of study Group 2 5 mg/dg/day D.D 0.0	Group 3 25 тур Кр/ day 0,2 0,4	Group 4 125 mg/sgiday 1.9 0.3
		Group Mean Loc Occasion w Group 1 O mg/kgiday	cal Skim Reaction eek 13 of study Group 2 5 mg/kg/day	Group 3 25 mg/kg/day	Graup 4 125 mg kgutay	Table 18	tie	Group Mean Loca Decession ves Group 1 Drog kgiday 0.0	l Skin Reaction ik 13 of study Group 2 5 mg/ug/day	Group 3 25 mg/kg/day	Group 4 125 mg/kgiday
a <u>) Maie anima'a</u>	Mean SD	Group Mean Loc Occasion w Group 1 0.0 0.0 10 0.0 0.0 0.0 0.0 0.0 0.0 0.0	cal Skim Reaction each 13 of study Group 2 5 mg/rgothy 0.0 0.0 19 19 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Group 3 28 mg/kg/day 0,2 0,4 10 0,2 0,4	Group 4 125 mg/hgday 2.1 0.3	Table 18 <u>(b) Ferrate anim</u>	Nean SD SD	Group Mean Loca Decasion vos Group 1 2 mgkgday 00 00 10	I Skin Reaction it 13 of study Group 2 5 mg/ug/day 10 0,0 0,0 0,0 0,0 0,0	Group 3 25 mg/kg/day 0.2 0.4 0.1 0.3	Group 4 125 mg/kgiday 19 0.3 10 18 0.4
a <u>) Male animala</u> 	Mean SD N	Group Mean Loc Occasion w Group 1 O mg/kg/day 0,0 10 10	Group 2 5 mg/kg/dey 00 10 00	Group 3 25 mg/kg/day 0.2 0.4 10 0.2	Group 4 125 mg/kgday 2.1 0.3 10 2.0	Table 18 <u>b) Ferrak anima</u> Eytherna	Mean No Mean	Group Mean Loca Decasion was Group 1 Dropkgiday 00 00 10	I Skn Readlon, k 13 of study Group 2 5 mg/ng/day 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Group 3 25 mp/kg/day 0.2 0.4 10 0.1	Group 4 125 mg/kgiday 1.9 0.3 10
a <u>) Male animala</u> 	Mean SD N Mean SD	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0.0 10 0.0 10 0.0 0.0 0.0 0.0 0.0 0.0 0	Cal Sim Reaction esk 13 of study Graup 2 5 mg/spday 0.0 0.0 0.0 10 0.0 0.0 10 0.0 0.0 0.0 0	Group 3 28 mg/kg/day 0,2 0,4 10 0,2 0,4	Group 4 125 mg/kgday 2,1 0,3 10 2,0 0,0	Table 18 <u>b) Ferrak anima</u> Eytherna	Mean SD N Maan SO N Mean SD	Group Mean Loca Decasion was Group 1 Dropkgrday 00 00 10 00 00 10 00 00 00 00	1 Skn Readlon, k 13 of study Group 2 5 mg/ng/day 0.0 0.0 0.0 0.0 0.0	Group 3 25 mp/sp/tay 0,2 0,1 0,1 0,3 10 0,1 0,3 10 0,4 0,5	Group 4 125 mg/kpiday 19 03 10 15 84 10 19 19 19 19 19 10 19 10 19 10 10 10 10 10 10 10 10 10 10 10 10 10
a) Male animals 	Mean SD N Mean SC N	Group Mean Loc Occasion w Group 1 0 mg/kgiday 0.0 10 10 0.0 0.0 10	cal Stan Reaction Group 2 5 mg/spidey 0.0 0.0 10 10 10 0.0 0.0 0.0 0.0 0.0 0.	Group 3 25 mg/kg/day 0.2 0.4 10 0.2 0.4 10	Graup 4 125 mg/kg/day 21 03 10 20 0.0 10 2.0	Table 18 <u>(b) Ferrate anima</u> Erytowna Edemie	ris Mean 3D N Maan SD N Mean	Group Mean Loca Decasion was Group 1 <i>D mg</i> kyddyr 00 10 10 10	1 Skin Reaction, ki 13 of study Group 2 5 mg/ug/day 0.0 10 0.0 0.0 10 0.0 0.0 0.0	Group 3 25 mg/kg/day 0.4 10 0.1 0.3 3,0 0 0.4	Group 4 123 mg/kpiday 0.3 10 15 8 8 4 10 13
a <u>) Alaie animalia</u> Erythema Edema	Mean SD N SC SC N Mean SD N Mean	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0.0 10 0.0 10 0.0 10 0.0 0.0 10 0.0 0.0	cal Skin Reaction exit 13 of study Group 2 5 mg/ng/dny 0,0 0,0 10 0,0 0,0 10 0,0 0,0 10 0,0 0,	Огомр 3 25 mg/kp/day 02 0,4 10 0,2 0,4 10 0,2 0,4 10 0,0 10 0,0 10 0,0 10 0,0 10	Croup 4 125 mg/kgday 2.1 0.3 10 2.0 0.3 10 2.0 0.3 10 2.0 0.0 7.0	Table 18 <u>(b) Ferrate anima</u> Erytowna Edomie	Mean SD N SD N Mean SD N Mean SD SD	Group Mean Loca Decasion was Group 1 0 mp kg/day 00 00 10 00 00 10 00 00 10 00 00 00 00	1 Skn Reaction, ik 13 of study Group 2 5 mg/sg/dgy D0 00 10 00 00 00 00 00 00 00 00 00 00 00	Group 3 25 mp top toy 0,2 0,4 10 0,1 0,3 10 0 0,4 0,5 10 0 0,4 0,5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0	Graup 4 125 mg/kpiday 0.3 10 1.8 0.4 10 10 13 0.3 10 10 10 10 10 10 0.0
a) Male animals 	Mean SD N Mean SD N SD N	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0,0 0,0 10 10 0,0 0,0 0,0 10 0,0 0,0 0,	cal Skim Reaction exek 13 of study Group 2 5 mg/kpdmy 0.0 0.0 10 10 0.0 10 10 10 10 10	Group 3 25 mg/kg/day 0.2 0.4 10 0.2 0.4 10 10 10 10	Group 4 125 mg/kgday 2.1 0.3 10 2.0 0.0 10 2.0 0.0 10 2.0 0.0 2.0 0.0 2.0 0.0 2.0 0.0 2.0	Table 18 <u>b) Perrais anima</u> Erythema Ecome Atoma	Mean SD N Mean SD N Mean N Mean Mean	Group Mean Loca Decasion vos Group 1 2 mg/kg/day 00 10 00 00 10 00 00 10 00 00 00 00 00	1 Skin Reaction, k 13 of study Group 2 5 mghagiday 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	Group 3 25 mp/kp/day 0.4 10 0.1 0.1 0.1 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	Group 4 125 mg/spitay 0.3 0.0 10 1.8 0.4 0 10 1.9 0.3 10 1.0 1.0
a) Advic antimatis Erythema Edema Atonia	Mean SD N Mean SD N Mean SD N Mean	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0.0 0.0 10 10 0.0 0.0 0.0 10 10 0.0 0.0	cal Skim Reaction exist 13 of study Group 2 5 mg/spday 0.0 0.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	Group 3 25 mg/kg/day 0.2 0.4 10 0.2 0.4 10 0.0 10 0.0 0.0 0.0 0.0	Group 4 125 mg/kgday 2.1 0.3 10 2.0 0.0 10 2.0 0.0 10 7.3 0.5 10 0.3	Table 18 <u>b) Perrais anima</u> Erythema Ecome Atoma	Mean SD N Mean SD N Mean N Mean N Mean N Mean	Group Mean Loca Decasion was group 1 0 0 00 10 10 00 00 10 10 00 00 10 10 00 00	1 Skin Reaction, ki 13 di sludy Grinup 2 5 mghugiday 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	Group 3 25 mp/sp/day 0,2 0,4 0,0 10 0,1 0,3 10 0,1 0,3 10 0,0 0,0 0,0	Group 4 123 mg/kpday 13 13 10 15 18 8 8 4 10 13 10 13 10 13 10 10 10 10 10 10 20 20 4
a <u>) Alaie animalia</u> Erythema Edema	Mean SD N Mean SD N Mean SD N N	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	cal Starn Reauction eals 13 of study Group 2 5 mg/ng/day 0.0 0.0 10 0.0 0.0 0.0 0.0 0.0 0.0 0.0	Group 3 28 mg/kg/day 0,2 0,4 10 0,2 0,4 10 0,0 0,0 10 10	Group 4 125 mg/kgday 2.1 0.3 10 2.0 0.0 10 2.0 0.0 10 7.3 0.5 10	Table 18 <u>b) Ferrals anima</u> Eythema Esoma Atoma Designamation	Mean SD N Mean SD N Mean SD N N	Group Mean Loca Decasion was 0 00 00 10 00 10 00 10 00 10 00 10 00 00 10 00 0	1 Skin Reaction, ki 13 di sludy Group 2 5 mgh/giday 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.0 0.	Group 3 25 mp/kg/day 0,4 10 0,1 0,1 0,5 10 0,0 0,5 0,5 0,0 0,0 10	Group 4 123 mg/kgiday 1.9 0.3 10 1.8 0.8 10 1.9 0.3 10 1.9 0.3 10 0.0 10
a) Advic antimatis Erythema Edema Atonia	Mean SD N Mean SC N Mean SD N Mean SD	Group Mean Loc Occasion w Group 1 0 mg/kg/day 0.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	cal Star Reaction eak 13 of study Group 2 5 mg/ng/day 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.	Group 3 28 mg/kg/day 0.2 0.4 10 0.2 0.4 10 0.0 10 10 10 0.0 10 0.0 0.0 0.0	Group 4 125 mg/kgday 2.1 0.3 10 2.0 0.0 10 2.0 0.0 10 7.3 0.5 10 0.3 0.5	Table 18 <u>b) Ferrals anima</u> Eythema Esoma Atoma Designamation	Mean SD N Mean SD N Mean SD N Mean SD SD	Group Mean Loca Decasion was group 1 0 0 00 10 10 00 00 10 10 00 00 10 10 00 00	1 Skin Reaction, ki 13 di sludy Grinup 2 5 mghugiday 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.0 10 0.0 0.	Group 3 25 mp/kg/day 0.4 10 0.1 0.5 10 0.6 0.6 0.0 10 0.0 0.0 0.0 0.0	Group 4 123 mg/kpday 13 13 10 15 18 8 8 4 10 13 10 13 10 13 10 10 10 10 10 10 20 20 4

OIT, CAS 26530-20-1

Figure 1







THOR GmbH	OIT, CAS 26530-20-1 Ju	ly, 2007
Section A6.4.3 J Annex Point A6.4	Subchronic inhalation toxicity test 90 days inhalation study	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [X]	Technically not feasible [] Scientifically unjustified [X]	
Limited exposure [X]	Other justification []	
Detailed justification:	The following situation applies to OIT during the manufacturing process and when used as preservative:	
	 OIT has a very low vapour pressure of 0.0031 hPa at 20 °C (OECD 104; "Determination of the Vapour Pressure of 2-Octyl-3(2H)-isothiazolone", 2002) 	
	 For the manufacturing of OIT and of b.p. containing OIT, a closed system technology applies. 	
	• For mixing and loading of OIT, due to the low vapour pressure, no inhalative exposure is expected.	
	• Further, the manufacturer stipulates in the technical information for any OIT containing formulation that during handling and processing the formation of aerosols should be avoided.	
	Since during the life cycle of OIT the inhalative route of exposure can be neglected, the information one would obtain from a 90 day inhalation study was considered to be not needed in order to determine the risk assigned. With view to animal welfare and to avoid unnecessary animal testing, particularly on mammals, it was therefore decided to abdicate such a study.	
	A 90 day inhalation toxicity test is not necessary for risk assessment since a OEL is in force in several member states. This limit value has been used for risk assessment purpose (see Doc IIA and Doc IIC).	
Undertaking of intended data submission []	Not applicable	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	17/09/2009	
Evaluation of applicant's justification		
Conclusion	Acceptable	
Remarks		

Section A6.4.3 J Annex Point A6.4	Subchronic inhalation toxicity test 90 days inhalation study
	COMMENTS FROM OTHER MEMBER STATE (specify)
Date	Give date of comments submitted
Evaluation of applicant's justification	Discuss if deviating from view of rapporteur member state
Conclusion	Discuss if deviating from view of rapporteur member state
Remarks	

Section A6.5-01 Annex Point 6.5	Long term toxicity in rats	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data []	Technically not feasible [] Scientifically unjustified [X]	
Limited exposure [X]	Other justification []	
Detailed justification:	OIT is a chemically reactive substance. Because of the irritating/corrosive and sensitising capabilities of OIT a chronic exposure to humans can be ruled out.	
	Given the lack of systemic toxicity, genotoxic potential and endocrine activity, it may be concluded that 2-n-octyl-4-isothiazolin-3-one is unlikely to demonstrate a so far unknown potential for chronic toxicity.	
References	2007, 2-n-Octyl-4-isothiazolin-3-one - Justification for the non-submission of data: Chronic toxicity/Oncogenicity, unpublished	
Undertaking of intended data submission []	Not applicable	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	17/04/2009	
Evaluation of applicant's justification		
Conclusion	acceptable	
Remarks	Further discussed in Doc IIA.	
	COMMENTS FROM OTHER MEMBER STATE (specify)	

Section A6.5-01 Annex Point 6.5	Long term toxicity in rats
Date	Give date of comments submitted
Evaluation of applicant's justification	Discuss if deviating from view of rapporteur member state
Conclusion	Discuss if deviating from view of rapporteur member state
Remarks	

Section A6.5-02	Long term repeated dose toxicity (oral feed)
Annex Point IIA6.5	18 months chronic toxicity/carcinogenicity study in mice

16.1	Reference	16 REFERENCE Officience 1975, Eighteen month study on the carcinogenic potential of RH-893 in mice Image: Carcinogenic potential of RH-893 in mice unpublished. Image: Carcinogenic potential of RH-893 in mice Image: Carcinogenic potential of RH-893 in mice	
16.2	Data protection	Yes	
16.2.1	Data owner	THOR GmbH	
16.2.2			
16.2.3	Criteria for data protection	Data submitted on existing A.S. for the purpose of its entry into Annex I.	
		17 GUIDELINES AND QUALITY ASSURANCE	
17.1	Guideline study	No (pre-guideline)	
17.2	GLP	No (pre-GLP)	
17.3	Deviations	Yes, numerous deficiencies with respect to recent guidelines	
		18 MATERIALS AND METHODS	
		In some fields the values indicated in the EC or OECD test guidelines are given as default values. Adopt, change or delete these default values depending on the true methodological parameters.	
18.1	Test material	Other: RH-893	
18.1.1	Lot/Batch number	RH-893	
18.1.2	Specification	Technical grade	

Sectio Annex IIA6.5	on A6.5-02 Point	Long term repeated dose toxicity (oral feed) 18 months chronic toxicity/carcinogenicity study in mice
18.1.2.	1 Description	Dark liquide
18.1.2.2	2 Purity	
18.1.2.	3 Stability	Stable. Dietary admixtures were prepared weekly.
18.2	Test Animals	Non-entry field
18.2.1	Species	mice
18.2.2	Strain	
18.2.3	Source	
18.2.4	Sex	Both sex
18.2.5	Age/weight at study	Age: 6 weeks
	initiation	Weight: 14.5 – 17.5 g in females; 17.0 – 20.5 g in males
18.2.6	Number of animals per group	125/sex/dose group
18.2.7	Control animals	Yes (negative and two positive control groups):
		2-Acetaminofluorene (AAF) in food and Dieethylnitrosamine (DEN) in drinking water
18.3	Administration/ Exposure	Oral
18.3.1	Duration of treatment	18 month (78 weeks)
18.3.2	Frequency of exposure	daily (feed admixture)
18.3.3	Postexposure period	No
18.3.4	<u>Oral</u>	
18.3.4.	1 Туре	in food
18.3.4.2	2 Concentration	0, 500, 1000 ppm in diet ad libitum
		substance uptake was not analysed (mg/kg bw)
18.3.4.	3 Vehicle	Not applicable
18.3.4.4	4 Concentration in vehicle	Not analysed.
18.3.4.	5 Total volume applied	Ad libitum
18.3.4.0	6 Controls	plain diet
18.4	Examinations	
18.4.1	Observations	
18.4.1.	l Clinical signs	No data
18.4.1.2	2 Mortality	yes
18.4.2	Body weight	Yes, once a week in 25/sex/dose
18.4.3	Food consumption	Not examined but ad libitum
18.4.4	Water consumption	Not examined but ad libitum

Section A6.5-02		Long term repeated dose toxicity (oral feed)	
Annex IIA6.5	Point	18 months chronic toxicity/carcinogenicity study in mice	
18.4.5	Ophthalmoscopic examination	по	
18.4.6	Haematology	no	
18.4.7	Clinical Chemisty	no	
18.4.8	Urinalysis	no	
18.5	Sacrifice and pathology		
18.5.1	Organ Weights	Yes organs: liver	
18.5.2	Gross and histopathology	Yes all dose groups (covers the usual tissues and not be a simple search of tumors) / reported only if effects organs: stomach, small and large intestines, liver, kidneys, spleen, lungs, female mammary gland, prostate, urinary bladder, skin, ovary, gonads.	
18.5.3	Other examinations	At 6 months, 25/sex/dose were sacrificed in view of findings (wheight depression, deaths) in positive control groups (Dimethylnitrosamine and 2-Aminofluorene.	
18.5.4	Statistics	Yes. Not described.	
18.6	Further remarks		
		19 RESULTS AND DISCUSSION	
		(Describe findings. If appropriate, include table. Sample tables are given below.)	
19.1	Observations		
19.1.1	Clinical signs	No data.	
19.1.2	Mortality	The survival of the mice through the 30th week was excellent for all groups with the exception of the DEN high dose group where survival was 50% and 64% respectively.	
		At eighteen months, the survival remained excellent (greater than 96%) for negative control and RH-893 treatment groups; the survival rate of the mice fed diets containing AAF was good for approximately 50 weeks at which time they began dying in increasing numbers with survival rates of 37% in males and 1% females at 18 months.	
19.2	Body weight gain	When compared to negative control mice, statistically significant lower body weights were observed in the mice receiving drinking water containing DEN and in the female mice fed diets containing AAF (600 ppm). These depressions in body weight were observed beginning the second week and present at the termination of the study at 78 weeks.	
		Statistically significant lower body weights were observed in both males and females received 1000 ppm RH-893 during the first few weeks of the study. By week 15 of the study, these differences were insignificant and remained comparable to the control group throughout the remainder of the study. Sporadic statistically significant body weight differences were observed in the 500 ppm group during the study and were judged not to be compound related.	
19.3	Food consumption	No data	

19.3 Food consumption No data and compound intake

OIT, CAS 26530-20-1

Section A6.5-02		Long term repeated dose toxicity (oral feed)						
Annex Point IIA6.5		18 months chronic toxicity/carcinogenicity study in mice						
19.4	Ophtalmoscopic examination	No data						
19.5	Blood analysis	No data						
19.5.1	Haematology	No data						
19.5.2	Clinical chemistry	No data						
19.5.3	Urinalysis	No data						
19.6	Sacrifice and pathology							
19.6.1	Organ weights	Of mice sacrificed after 26 or 30 weeks of treatment, statistically significant increases in the liver/body weight ratios were observed in both male and female mice receiving drinking water containing 6-4 mg/kg/day DEN and females receiving drinking water containing 4 mg/kg/day DEN. Males receiving diets containing 500 ppm RH-893 showed a slight but statistically significant increase in the liver/body weight ratio while males receiving diets containing 1000 ppm RH-893 showed a slight but statistically significant lower liver/body weight ratio. At termination (78 weeks), the liver/body weight ratio was statistically significantly increased in male mice receiving diets containing 500 ppm RH 893 and female mice receiving diets						
19.6.2	Gross and histopathology	 containing 300 ppm RH-893 and remate fince receiving dicts containing 1000 ppm RH-893. These differences in liver/body weight ratio of the RH-893 treated mice are judged to be of no toxicological significance. Histopathologic examination of mice sacrificed after 26 or 30 weeks of treatment with DEN revealed "diffuse and nodular carcinoma" of the livers in most mice and bronchiectasis in many of the mice. Histopathologic examination of mice receiving RH-893 for 30 weeks demonstrated no pathologic or cytologic changes attributable to the administrationof RH-893. Of the non-neoplastic lesions observed, only hyperplasia of the urinary bladder in the male mice treated with AAF, is considered to be of toxicologic significance. A higher incidence of neoplastic lesions of the liver and urinary bladder was observed in both male 						
		and female mice fed diets containing AAF and is considered to be compound related. The incidence and types of neoplastic lesions in the RH-893 mice are those expected to occur spontaneously in this strain of mouse.						
19. 7	Other	-						
20.1	Materials and	20 APPLICANT'S SUMMARY AND CONCLUSION RH-893 at concentrations of 0, 500 and						
20.1	materials and methods	at concentrations of 0, 500 and 1000 ppm admixed with feed was fed to 125 mice/sex/group for 18 months. At 6 months, 25/sex/dose were sacrificed.						
20.2	Results and discussion	Body weights were reduced at 1000 ppm in both sexes, especially early in the study. No adverse effect identified.						

OIT, CAS 26530-20-1

Section A6.5-02 Annex Point IIA6.5		Long term repeated dose toxicity (oral feed) 18 months chronic toxicity/carcinogenicity study in mice				
20.3	Conclusion	No oncogenic response to exposure with up to 1000 ppm OIT.				
20.3.1	LO(A)EL	No adverse effect identified.				
20.3.2	NO(A)EL	1000 ppm OIT in diet				
20.3.3	Other					
20.3.4	Reliability	3				
20.3.5	Deficiencies	Yes				
		Stability of test substance in the diet was not analysed (recovery) and substance uptake was not analysed However, palatability of test diet was achieved.				
		Examinations of several endpoints were not addressed. But fullterm survival and no-incidence with regard to typical endpoints in comparison to known carcinogenes were successfully demonstrated.				

	Evaluation by Competent Authorities					
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted					
	EVALUATION BY RAPPORTEUR MEMBER STATE					
Date	17/04/2009					
Materials and Methods						
Results and discussion						
Conclusion						
Reliability	3					
Acceptability	Acceptable					
Remarks	In agreement with the applicant's assessment.					
	COMMENTS FROM (specify)					
Date	Give date of comments submitted					
Materials and Methods	Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state					
Results and discussion	Discuss if deviating from view of rapporteur member state					
Conclusion	Discuss if deviating from view of rapporteur member state					
Reliability	Discuss if deviating from view of rapporteur member state					
Acceptability	Discuss if deviating from view of rapporteur member state					
Remarks						

THOR GmbH OIT, CAS 26530-20-1 July, 2007

Table I: Eighteen Month Study on the Carcinogenic Potential of RH-893 in Mice

Summary of Findings

Group	Experimental Compound	Dose level	Sex	18 Month ^b Survivors/Initial	Body Wt. (g)		Liver/Body Wt. x 10 ⁻³		NoofLesions/Numberofmiceexamined			
		Diet (ppm)			6 Mo.	18 Mo.	6 Mo.	18 Mo.	Non-neoplastic	Neoplastic	Metastasis	
1	negative	0	М	98/100	30.6	33.8	48.9	49.6	7/100	8/100	0/100	_
	control		F	96/103	28.1	34.1	49.1	48.7	13/100	2/100	0/100	
2	RH-893	500	М	97/100	32.3	36.5	52.9*	52.3*	-	-	-	
			F	99/100	285	33.7	50.9	49.2	-	-	-	
3	RH-893	1000	М	97/100	30.4	34.0	46.4 *	50.6	1/48	4/48	0/48	
			F	97/100	27.7	33 1	51.4	50.8*	2/48	5/48	0/48	
4	AAF ^d	600	М	37/100	29.9	32.4	-	-	14/100	50/100	2/100	
			F	1/100	24.9*	25.1 °	-	-	8/98	117/98	4/98	
		Daily Intake										
		mg/kg/day										
5	DEN°	4	М	-	24.6*	-	52.3		-	-	-	
			F	-	19.4*	-	71.6*		-	-	-	
6	DEN ^e		М	-	20.4*	-	68.6*		-	-	-	
			F	-	17.1*	-	101.0*		-	-	-	* sign

* significantly different from control p< 0.05

^a Re-tabulated from: Appendix A, Tables

^b Does not include mice sacrificed at 30weeks.

° Week 70 data.

^d 2-Acetamidofluorene

^e Diethyl nitrosamine (DEN) administered in drinking water.

Table II: Eighteen Month Study an the Carcinogenic Potential of RH-893 in Mice

Summary of Histopathologic Lesions

	ľ	Male		Female			
No. of Mice Examined	Neg. Control	AAF ^a	RH-893	Neg. Control	AAF	RH-893	
	100	100	1000 ppm 48	100	98	1000 ppm	
Non-neoplastic Lesions			40			<u> </u>	
Hyperplasia bladder		.3					
Infections & granulomas	3			4	5		
Others	4	1	1	9	3	2	
Total	7	14	1	13	8	2	
Neoplastic Lesions							
Urinary bladder		15			17		
Liver	7	30	3		89		
Lymph node	1	3			3	3	
Others		2	1		8	2	
Total	8	50	4	2	117	5	

^a 2-Acetamidofluorene